170 related articles for article (PubMed ID: 21567102)
1. Expression and role of SIRT1 in hepatocellular carcinoma.
Choi HN; Bae JS; Jamiyandorj U; Noh SJ; Park HS; Jang KY; Chung MJ; Kang MJ; Lee DG; Moon WS
Oncol Rep; 2011 Aug; 26(2):503-10. PubMed ID: 21567102
[TBL] [Abstract][Full Text] [Related]
2. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth.
Chen J; Zhang B; Wong N; Lo AW; To KF; Chan AW; Ng MH; Ho CY; Cheng SH; Lai PB; Yu J; Ng HK; Ling MT; Huang AL; Cai XF; Ko BC
Cancer Res; 2011 Jun; 71(12):4138-49. PubMed ID: 21527554
[TBL] [Abstract][Full Text] [Related]
3. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma.
Zhang ZY; Hong D; Nam SH; Kim JM; Paik YH; Joh JW; Kwon CH; Park JB; Choi GS; Jang KY; Park CK; Kim SJ
J Hepatol; 2015 Jan; 62(1):121-30. PubMed ID: 25131770
[TBL] [Abstract][Full Text] [Related]
4. Inhibition mechanism of a newly cloned candidate tumor suppressor gene JST during hepatocarcinogenesis and its abnormal expression in human hepatocellular carcinoma from Qidong liver cancer risk area, China.
Dong-Dong L; Xi-Ran Z
Hepatogastroenterology; 2004; 51(56):515-25. PubMed ID: 15086194
[TBL] [Abstract][Full Text] [Related]
5. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness.
Hsu HC; Tseng HJ; Lai PL; Lee PH; Peng SY
Cancer Res; 1993 Oct; 53(19):4691-4. PubMed ID: 8402647
[TBL] [Abstract][Full Text] [Related]
6. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.
Chen HC; Jeng YM; Yuan RH; Hsu HC; Chen YL
Ann Surg Oncol; 2012 Jun; 19(6):2011-9. PubMed ID: 22146883
[TBL] [Abstract][Full Text] [Related]
7. GEP associates with wild-type p53 in hepatocellular carcinoma.
Cheung ST; Wong SY; Lee YT; Fan ST
Oncol Rep; 2006 Jun; 15(6):1507-11. PubMed ID: 16685387
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis.
Peng SY; Lai PL; Pan HW; Hsiao LP; Hsu HC
Oncol Rep; 2008 Apr; 19(4):1045-53. PubMed ID: 18357395
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of SIRT1 promotes metastasis through epithelial-mesenchymal transition in hepatocellular carcinoma.
Hao C; Zhu PX; Yang X; Han ZP; Jiang JH; Zong C; Zhang XG; Liu WT; Zhao QD; Fan TT; Zhang L; Wei LX
BMC Cancer; 2014 Dec; 14():978. PubMed ID: 25522783
[TBL] [Abstract][Full Text] [Related]
10. [Expression of telomerase reverse transcriptase and its relationship with tumor suppressor gene p53 in HCC].
Dai D; Zhai W; Zhu T; Zhu H; Ling Y
Zhonghua Gan Zang Bing Za Zhi; 2001 Jul; 9 Suppl():79-81. PubMed ID: 11509149
[TBL] [Abstract][Full Text] [Related]
11. Deletion of chromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 and p15/MTS2 gene protein in hepatocellular carcinomas.
Shao J; Li Y; Li H; Wu Q; Hou J; Liew C
Chin Med J (Engl); 2000 Sep; 113(9):817-22. PubMed ID: 11776078
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of SIRT1 in hepatocellular carcinoma.
Song S; Luo M; Song Y; Liu T; Zhang H; Xie Z
J Coll Physicians Surg Pak; 2014 Nov; 24(11):849-54. PubMed ID: 25404446
[TBL] [Abstract][Full Text] [Related]
13. ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma.
Kang YH; Ji NY; Lee CI; Lee HG; Kim JW; Yeom YI; Kim DG; Yoon SK; Kim JW; Park PJ; Song EY
Amino Acids; 2011 Mar; 40(3):1003-13. PubMed ID: 20821239
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation.
Caruso ML; Valentini AM
Anticancer Res; 1999; 19(5B):3853-6. PubMed ID: 10628323
[TBL] [Abstract][Full Text] [Related]
15. Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma.
Itoh T; Shiro T; Seki T; Nakagawa T; Wakabayashi M; Inoue K; Okamura A
Int J Mol Med; 2000 Aug; 6(2):137-42. PubMed ID: 10891556
[TBL] [Abstract][Full Text] [Related]
16. High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma.
Anzola M; Saiz A; Cuevas N; Lopez-Martinez M; Martinez de Pancorbo MA; Burgos JJ
J Viral Hepat; 2004 Nov; 11(6):502-10. PubMed ID: 15500550
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the expression of beta-catenin in hepatocellular carcinoma in areas with high and low levels of exposure to aflatoxin B1.
Chen Ban K; Singh H; Krishnan R; Fong Seow H
J Surg Oncol; 2004 Jun; 86(3):157-63. PubMed ID: 15170655
[TBL] [Abstract][Full Text] [Related]
18. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Gramantieri L; Giovannini C; Veronese A; Ferracin M; Sabbioni S; Calin GA; Grazi GL; Croce CM; Tavolari S; Chieco P; Negrini M; Bolondi L
Cancer Res; 2009 Jul; 69(14):5761-7. PubMed ID: 19584283
[TBL] [Abstract][Full Text] [Related]
19. DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control.
Chang PC; Chi CW; Chau GY; Li FY; Tsai YH; Wu JC; Wu Lee YH
Oncogene; 2006 Mar; 25(14):1991-2003. PubMed ID: 16301996
[TBL] [Abstract][Full Text] [Related]
20. [Determination of expression of eight p53-related genes in hepatocellular carcinoma with tissue microarrays].
Zhu MH; Ni CR; Zhu Z; Li FM; Zhang SM
Ai Zheng; 2003 Jul; 22(7):680-5. PubMed ID: 12866955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
